IP Verse

Genotype And Dose-Dependent Response To An Asbti In Patients With Bile Salt Export Pump Deficiency

Patent No. EP3923943 (titled "Genotype And Dose-Dependent Response To An Asbti In Patients With Bile Salt Export Pump Deficiency") was filed by Mirum Pharmaceuticals on Feb 12, 2020. The application was issued on Jul 31, 2024.

Patent Summary

Modulating bile acid transport in cholestatic liver disease through targeted inhibition of apical sodium-dependent bile acid transporters (ASBTIs). The ASBTIs specifically target the apical bile acid export pump (BSEP) to prevent bile acid reabsorption and promote bile acid excretion. The treatment modulates the ASBTI dosage to achieve optimal bile acid clearance while maintaining bile acid levels within therapeutic ranges. The method utilizes genetic testing to predict the response to ASBTI therapy based on the patient's ABCB11 gene sequence, which determines the functional status of the BSEP protein.

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GENERICS UKApr 30, 2025RUSSELL
SANDOZApr 30, 2025MAIWALD

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3923943

MIRUM PHARMACEUTICALS
Application Number
EP20755296A
Filing Date
Feb 12, 2020
Status
Granted And Under Opposition
Jun 27, 2024
Publication Date
Jul 31, 2024
External Links
Slate, Register , Google Patents